Ocular Physiologically Based Pharmacokinetic Modeling for Ointment Formulations

Author:

Le Merdy MaximeORCID,Spires Jessica,Lukacova Viera,Tan Ming-Liang,Babiskin Andrew,Xu Xiaoming,Zhao Liang,Bolger Michael B.

Abstract

Abstract Purpose The purpose of this study is to show how the Ocular Compartmental Absorption & Transit (OCAT™) model in GastroPlus® can be used to characterize ocular drug pharmacokinetic performance in rabbits for ointment formulations. Methods A newly OCAT™ model developed for fluorometholone, as well as a previously verified model for dexamethasone, were used to characterize the aqueous humor (AH) concentration following the administration of multiple ointment formulations to rabbit. The model uses the following parameters: application surface area (SA), a fitted application time, and the fitted Higuchi release constant to characterize the rate of passage of the active pharmaceutical ingredient from the ointment formulations into the tears in vivo. Results Parameter sensitivity analysis was performed to understand the impact of ointment formulation changes on ocular exposure. While application time was found to have a significant impact on the time of maximal concentration in AH, both the application SA and the Higuchi release constant significantly influenced both the maximum concentration and the ocular exposure. Conclusions This initial model for ointment ophthalmic formulations is a first step to better understand the interplay between physiological factors and ophthalmic formulation physicochemical properties and their impact on in vivo ocular drug pharmacokinetic performance in rabbits.

Funder

U.S. Food and Drug Administration

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Organic Chemistry,Pharmaceutical Science,Pharmacology,Molecular Medicine,Biotechnology

Reference39 articles.

1. Electronic Code of Federal Regulations (eCFR) [Internet]. Electronic Code of Federal Regulations (eCFR). 2020. Available from: https://www.ecfr.gov/. Accessed 15 Mar 2020.

2. Choi SH, Lionberger RA. Clinical, pharmacokinetic, and in vitro studies to support bioequivalence of ophthalmic drug products. AAPS J. 2016;18(4):1032–8.

3. Harigaya Y, Jiang X, Zhang H, Chandaroy P, Stier EM, Pan Y. Bioequivalence study methods with pharmacokinetic endpoints for topical ophthalmic corticosteroid suspensions and effects of subject demographics. Pharm Res. 2018;36(1):13.

4. U.S. FDA. Draft guidance on tobramycin [internet]. 2019. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/psg/Tobramycin%20ophthalmic%20ointment%200.3%20NDA%20050555%20PSG%20Page%20RC%20May%202019.pdf. Accessed 02 May 2020.

5. US. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations [Internet]. 2018. Available from: https://www.accessdata.fda.gov/scripts/cder/ob/. Accessed 04 Aug 2020.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3